TrialAnnals of the rheumatic diseases2012

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial.

Jeffrey R Curtis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.